<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="54882">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02391675</url>
  </required_header>
  <id_info>
    <org_study_id>12.17/infect12.03</org_study_id>
    <nct_id>NCT02391675</nct_id>
  </id_info>
  <brief_title>The Hasselt APPendicitis Immunology and Environmental Cohort STudy</brief_title>
  <acronym>HAPPIEST</acronym>
  <official_title>The Hasselt APPendicitis Immunology and Environmental Cohort STudy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hasselt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jessa Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hasselt University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Hasselt Appendicitis Immunology and Environmental Study (HAPPIEST) aims at
      characterizing factors that influence the development and severity of acute appendicitis. In
      a cohort of 300 patients and 300 controls, environmental factors as well as genetic make-up
      of the innate immune system, focusing mainly on pattern recognition, will be analyzed in
      order to gain insight in their relative importance in the pathology of appendicitis.
      Furthermore, populations of micro-organisms present in the gut of patients will be
      characterized, and the interaction between relevant micro-organisms and the innate immune
      system will be analyzed.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Years</target_duration>
  <primary_outcome>
    <measure>Genetic susceptibility</measure>
    <time_frame>Within 2 years after inclusion of the last patient</time_frame>
    <description>DNA sample collected at inclusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunology composite outcome</measure>
    <time_frame>within 4 years</time_frame>
    <description>ex vivo peripheral blood mononuclear cell (PBMC) stimulation experiments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Environmental factors</measure>
    <time_frame>Within 6 months after inclusion of the last patient</time_frame>
    <description>Questionnaire filled in at inclusion</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Quality of life</measure>
    <time_frame>4-6 weeks after inclusion for appendicitis</time_frame>
    <description>Questionnaire at outpatient visit</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Appendicitis</condition>
  <arm_group>
    <arm_group_label>Appendicitis patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood, plasma, serum, appendix tissue, stool
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients are asked to participate after presenting with acute appendicitis at the
        emergency room of Jessa Ziekenhuis, Hasselt. If the patient fits the criteria, and
        informed consent is signed, the patient is included in the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute appendicitis

          -  Appendectomy within 7 days after onset of symptoms

          -  Signed informed consent

        Exclusion Criteria:

          -  Appendectomy 7 days or more after onset of symptoms

          -  Participation in any clinical investigational drug study within 4 weeks of screening

          -  Severe, life-threatening disease with a life expectancy of less than 2 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Inge C Gyssens, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hasselt University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toon H Peeters, MSc</last_name>
    <phone>+32 11 30 98 27</phone>
    <email>toon.peeters@jessazh.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Inge C Gyssens, MD, PhD</last_name>
    <phone>+ 32 11 30 94 85</phone>
    <email>inge.gyssens@jessazh.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jessa Ziekenhuis</name>
      <address>
        <city>Hasselt</city>
        <state>Limburg</state>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toon H Peeters, MSc</last_name>
      <phone>+32 11 30 98 27</phone>
      <email>toon.peeters@jessazh.be</email>
    </contact>
    <contact_backup>
      <last_name>Inge C Gyssens, MD, PhD</last_name>
      <phone>+32 11 30 94 85</phone>
      <email>inge.gyssens@jessazh.be</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6500-6546, 6663</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inge C Gyssens, MD PhD</last_name>
      <phone>+31 24 361 8819</phone>
      <email>inge.gyssens@radboudumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Mihai G Netea, MD PhD</last_name>
      <phone>+31 24 361 8819</phone>
      <email>m.netea@aig.umcn.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Stappers MH, Thys Y, Oosting M, Plantinga TS, Ioana M, Reimnitz P, Mouton JW, Netea MG, Joosten LA, Gyssens IC. Polymorphisms in cytokine genes IL6, TNF, IL10, IL17A and IFNG influence susceptibility to complicated skin and skin structure infections. Eur J Clin Microbiol Infect Dis. 2014 Dec;33(12):2267-74. doi: 10.1007/s10096-014-2201-0.</citation>
    <PMID>25022448</PMID>
  </reference>
  <reference>
    <citation>Stappers MH, Thys Y, Oosting M, Plantinga TS, Ioana M, Reimnitz P, Mouton JW, Netea MG, Joosten LA, Gyssens IC. TLR1, TLR2, and TLR6 gene polymorphisms are associated with increased susceptibility to complicated skin and skin structure infections. J Infect Dis. 2014 Jul 15;210(2):311-8. doi: 10.1093/infdis/jiu080.</citation>
    <PMID>24511099</PMID>
  </reference>
  <reference>
    <citation>Rivera-Chavez FA, Peters-Hybki DL, Barber RC, Lindberg GM, Jialal I, Munford RS, O'Keefe GE. Innate immunity genes influence the severity of acute appendicitis. Ann Surg. 2004 Aug;240(2):269-77.</citation>
    <PMID>15273551</PMID>
  </reference>
  <reference>
    <citation>Schnitzler F, Friedrich M, Wolf C, Angelberger M, Diegelmann J, Olszak T, Beigel F, Tillack C, Stallhofer J, GÃ¶ke B, Glas J, Lohse P, Brand S. The NOD2 p.Leu1007fsX1008 mutation (rs2066847) is a stronger predictor of the clinical course of Crohn's disease than the FOXO3A intron variant rs12212067. PLoS One. 2014 Nov 3;9(11):e108503. doi: 10.1371/journal.pone.0108503.</citation>
    <PMID>25365249</PMID>
  </reference>
  <verification_date>March 2015</verification_date>
  <lastchanged_date>March 12, 2015</lastchanged_date>
  <firstreceived_date>February 26, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hasselt University</investigator_affiliation>
    <investigator_full_name>prof. dr. Inge Gyssens</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Appendicitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
